In furtherance of her research and involvement in UCI’s doctorial program, currently as a 4th year PhD candidate, Kyleen Castro was awarded her second Masters degree from the Department of Molecular Biology and Biochemistry in the Department of Biological Sciences.
Kyleen Castro advances to candidacy in UCI PhD program. Her project is preliminarily entitled “Investigation into the Synthetic Lethality of CDK9 Inhibition on VHL-Deficient Clear Cell Renal Carcinoma.
Doctorial Student, Kyleen Castro, was awarded the 2023 Regenicin Biological Health Program Grant for her work in the synthetic lethality of CDK9 inhibition on VHL-Deficient Clear Cell Renal Cell Carcinomas
Doctorial students, Luke Nelson and Kyleen Castro co-authored a new paper published in Cell Cycle describing the synthetic lethality of CDK inhibitor Dinaciclib on VHL-Deficient clear cell Renal Cell Carcinomas. Nelson, L.J., Castro, K.E., Xu, B., Li, J., Dinh, N.B., Thompson, J.M., Woytash, J., Kipp, K.R. & Razorenova, O.V. Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma. Cell Cycle, 1-17 (2022).
Lab Post-Doc, Jordan Woytash, was awarded a T32 Fellowship which will go through May 2021. Congratulations Jordan!